Qingwen Jiedu Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is an extract-derived active pharmaceutical intermediate, not a finished ready-to-administer veterinary medicinal product. The manufacturing documentation designation QJD-VG-API separates the veterinary-grade extract from the finished oral solution and from crude botanical mixtures. It is supplied in three physical grades: a spray-dried powder for tablet and capsule wet granulation, a vacuum-dried granulate for premix and powder feeding, and a low-bioburden liquid concentrate for oral solution and injectable line dilution. Identity is confirmed by high-performance liquid chromatography with diode-array detection against pharmacopoeial marker compounds. Because the formula is a multi-herb system, the marker set typically includes flavonoid glycosides and iridoid glycosides; exact retention-time windows and relative response factors are taken from the current Chinese Veterinary Pharmacopoeia monograph. Published data for this specific configuration is limited, so initial formulation trials should not replace batch-specific assay results with literature-only values.

What quality boundary separates oral premix grade from injection-grade concentrate?

The controlling boundary is not chemical potency but microbial and endotoxin burden. For oral tablet, capsule, powder, granule, and premix manufacture, the API is normally released with total aerobic microbial count not exceeding 10³ CFU/g and total combined yeasts and moulds not exceeding 10² CFU/g, tested according to USP <61> or the equivalent Chinese Pharmacopoeia general chapter. For injection-grade liquid concentrate, the same botanical extract must meet a stricter total aerobic count ceiling of 10² CFU/g and a bacterial endotoxin limit derived from the K/M formula in USP <85>; the allowable endotoxin load depends on target species, route, and maximum dose. The shift from oral to injectable grade is therefore not achieved by simple dilution. It requires a dedicated manufacturing train using depyrogenated tanks, single-pass tangential-flow filtration, and cleanrooms classified under ISO 14644-1:2015 as ISO Class 7 for formulation and ISO Class 5 for personnel-controlled interventions.

On a rotary tablet press operating at 60,000 tablets/h, spray-dried extract with a Hausner ratio above 1.35 tends to produce weight variation if the feed frame speed is not reduced. Typical direct-compression formulations containing 20–35 wt% QJD-VG-API require microcrystalline cellulose and crospovidone at 2–5 wt% to maintain compressibility, because the extract particles alone exhibit poor plastic deformation. In wet granulation, a top-spray fluid-bed granulator with inlet-air temperature 50–65°C and final moisture 1.5–3.0% produces granules with acceptable compression properties. If relative humidity exceeds 60%, the extract surface softens and picking occurs on the die table; tooling should be cooled and forced-air dust extraction maintained. Hardness values between 60 N and 100 N and friability below 1.0% are typical acceptance limits for finished tablets, not attributes of the API itself.

When the same API enters tablet, capsule, and premix lines, particle-size drift becomes the dominant risk

Particle-size drift after reworking is a known production bottleneck on multi-line botanical API processes. A spray-dried QJD-VG-API powder with an initial D50 of 45–65 µm and D90 below 150 µm may shift after repeated screw conveying or ribbon blending; fines generated by attrition lower the D50 by 10–25 µm, increasing dust and segregation. Blend uniformity in premix manufacture is measured by stratified sampling under the FDA guidance for powder blends and finished dosage units; a coefficient of variation below 5.0% for 10 sampled locations is generally required to support continued use of the blend. For capsules, a two-piece hard gelatin capsule filling machine operating at 60,000 capsules/h requires a powder bulk density of 0.45–0.65 g/mL; low-density extract may need roll compaction at 4–6 MPa roll pressure before encapsulation. The same extract grade is not automatically suitable for all three lines; a batch that passes tablet blend uniformity may fail premix homogeneity because of density differences with mineral carriers such as calcium carbonate or wheat bran.

Because injection-grade liquid concentrates are filtered through polyethersulfone or PVDF membranes, extract-associated polysaccharides and tannins can foul a 0.2 µm sterilising-grade cartridge. A two-stage 0.45/0.2 µm prefilter/sterilising filter train is commonly specified, but filter capacity must be confirmed by real-time integrity testing. Heat pre-treatment at 72°C for 15 s is used in some liquid concentrate lines to reduce bioburden without extensive degradation of heat-labile iridoid glycosides; treatment at 90–100°C for 10–20 min provides greater microbial reduction but may alter marker content. Endotoxin removal is not assumed with filtration; upstream control of gram-negative bacterial lysis is required. For powders intended for injection, micronization to D90 below 25 µm is sometimes requested, but published data for this specific botanical extract is limited, and syringeability must be validated in the finished formulation rather than inferred from particle-size alone. Particulate matter in the final injectable is controlled under USP <788>.

A multi-herb API cannot be reduced to a single dissolution specification

Because QJD-VG-API contains multiple phytochemical classes with pH-dependent solubility, dissolution behavior in a USP <711> apparatus 2 at 50 rpm and 37±0.5°C may vary with marker compound. Flavonoid glycosides such as baicalin tend to show higher release in phosphate buffer pH 6.8 than in 0.1 N hydrochloric acid; iridoid glycosides may release more rapidly. A single Q value is therefore not assigned to the API. Finished product dissolution specifications are established per formulation and per marker, using at least two media. This distinguishes the veterinary-grade herbal extract from single-molecule synthetic APIs such as enrofloxacin or ivermectin, where a single dissolution specification is pharmacopoeially defined. The same principle applies to content uniformity: because the extract is not a single chromatographic peak, the assay is expressed as total marker content or total extractable solids, not as a single active moiety.

The principal difference between QJD-VG-API and crude Qingwen Jiedu powders is the reduction of plant fibrous material and the application of a chromatographic identity test; the API is therefore suited to high-speed tablet presses and aqueous injection lines, whereas crude powder is limited to traditional premix blending at higher inclusion rates. Compared with synthetic veterinary active pharmaceutical ingredients, the multi-herbal extract carries a wider impurity profile and greater hygroscopicity, so the supplier and the formulator must control water activity and residual solvent profile under VICH GL18 rather than relying on a single melting point. Compared with the finished Qingwen Jiedu Oral Solution, the API is not adjusted to final pH, not preserved, and not release-tested for clinical administration; it remains an intermediate whose acceptance criteria are defined for the next manufacturing step.